Geneva, May 28 -- International Clinical Trials Registry received information related to the study (NCT06964568) titled 'TDLN-sparing RT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC' on May 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Fudan University
Condition:
Esophageal Carcinoma
Radiotherapy
Immunotherapy
Intervention:
Drug: PD-1 inhibitor
Radiation: TDLN-sparing radiotherapy
Recruitment Status: Recruiting
Phase: Phase 3
Date of First Enrollment: February 1, 2025
Target Sample Size: 452
Countries of Recruitment:
China
To know more, visit https://clinicaltr...